Will Glasgibb/Glasgib be included in medical insurance in 2025?

Glasdegib is an oral small molecule drug primarily used to treat acute myeloid leukemia (AML). It is an inhibitor of the Hedgehog signaling pathway. It blocks this pathway by inhibiting Smoothened (SMO) protein, thereby inhibiting the growth and survival of leukemia cells. The drug is often used in combination with low-dose cytarabine (LDAC) for adult patients with newly diagnosed AML who are not candidates for intensive chemotherapy. Its mechanism of action is different from traditional chemotherapy, providing a new treatment option for elderly or weak patients.

Glasgib was approved by the U.S. Food and Drug Administration (FDA) in 2018 and has been approved in many countries. However, as of 2025, the drug has not yet been officially launched in China, so it is not available in the domestic market through conventional medical channels. Since it has not entered the approval process of the National Medical Products Administration (NMPA), its medical insurance reimbursement status is also unclear. At present, if domestic patients need to use Glass Gibb, they usually need to obtain it through cross-border medical treatment or overseas purchasing, but the price is higher and there are certain legal and safety risks.

There is currently no official and precise information on whether Glassgibb will be included in China's medical insurance in 2025. Usually, the introduction of imported anti-cancer drugs needs to go through multiple stages such as approval, clinical trials, and price negotiations. The adjustment of the medical insurance catalog usually also needs to be based on factors such as the clinical value of the drug, market demand, and the affordability of the medical insurance fund. Therefore, domestic patients and medical staff need to pay close attention to the latest announcements from the National Medical Insurance Administration, the Food and Drug Administration and relevant medical institutions to understand the progress of Glassgib's launch in China and possible medical insurance coverage. Until then, patients still need to rely on other feasible treatment options, such as existing chemotherapy drugs or other targeted therapies, to control the disease and improve survival.

Reference materials:https://go.drugbank.com/drugs/DB11978